Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

August 31, 2017

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib & Capecitabine

Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.

Trial Locations (3)

87102

University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque

87106

University of New Mexico Cancer Center, Albuquerque

87110

Cancer Center at Presbyterian Hospital, Albuquerque

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

New Mexico Cancer Research Alliance

OTHER